Auna SA is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators, financial performance, and lack of positive catalysts suggest a cautious approach. Holding or waiting for more clarity after the upcoming financial results may be more prudent.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 40.238, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 5.38), with resistance at 5.968. Overall, the technical indicators do not suggest a strong buy signal.
Auna SA is a leading healthcare services provider in Latin America, managing 1.4 million healthcare plans. Upcoming Q1 2026 financial results and conference call could provide more clarity on the company's performance.
Analyst ratings are mixed, with a recent downgrade to Neutral. Technical indicators show bearish momentum, and there are no significant insider or hedge fund trading trends.
In Q3 2025, revenue dropped by -0.86% YoY, net income fell by -50.87% YoY, EPS declined by -50.76% YoY, and gross margin decreased by -5.92%. These metrics indicate a challenging financial environment for the company.
Analyst sentiment is mixed. BTG Pactual downgraded Auna to Neutral with a $7 price target, while HSBC recently upgraded it to Buy with a $6.90 price target. The price targets suggest limited upside from the current price of $5.4577.